UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 588

Sortiert nach

185 SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA AFTER CHRONIC MYELOMONOCYTIC LEUKEMIA: AN UNCOMMON CASE REPORT OF CLONAL EVOLUTION

Leukemia research, 2015-04, Vol.39, p.S92-S93

2015

Volltextzugriff (PDF)

Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia

Oncogene, 2012-07, Vol.31 (30), p.3536-3546

2012

Volltextzugriff (PDF)

205 A SINGLE CENTER REPORT OF THERAPEUTIC STRATEGIES IN PATIENTS WITH ATYPICAL CML (ACML) AND UNCLASSIFIED MDS/MPN (MDS/MPN-U)

Leukemia research, 2015-04, Vol.39, p.S102-S102

2015

Volltextzugriff (PDF)

P-283 Efficacy of salvage with decitabine (DAC) for high-risk (HR)-MDS and advanced CMML after azacitidine (AZA) treatment failure

Leukemia research, 2013-05, Vol.37, p.S150-S150

2013

Volltextzugriff (PDF)

Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine

Leukemia, 2011-07, Vol.25 (7), p.1207-1209

2011

Volltextzugriff (PDF)

Prévalence de l’ostéoporose chez les patients avec syndrome myélodysplasique

Revue du rhumatisme (Ed. française : 1993), 2021-12, Vol.88, p.A67-A68

2021

Volltextzugriff (PDF)

Les facteurs associés au risque d’ostéoporose au cours des syndromes myélodysplasiques

Revue du rhumatisme (Ed. française : 1993), 2022-12, Vol.89, p.A85-A85

2022

Volltextzugriff (PDF)

Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: MESENCHYMAL STROMAL CELLS OF THE BONE MARROW NICHE CONTRIBUTE TO THE PROINFLAMMATORY PHENOTYPE OF CMML MONOCYTES THROUGH IGFBP2

Leukemia research, 2023-05, Vol.128, p.107219, Article 107219

2023

Volltextzugriff (PDF)

Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: CXCL8 SECRETED BY IMMATURE GRANULOCYTES INHIBITS WILD-TYPE STEM AND PROGENITOR CELL EXPANSION IN CHRONIC MYELOMONOCYTIC LEUKEMIA

Leukemia research, 2023-05, Vol.128, p.107214, Article 107214

2023

Volltextzugriff (PDF)

Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: CMML PATIENTS WITH LOW EXPRESSION OF TP53 POINT TO AML TRANSFORMATION

Leukemia research, 2023-05, Vol.128, p.107197, Article 107197

2023

Volltextzugriff (PDF)

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

Leukemia research, 2012-04, Vol.36 (4), p.397-400

2012

Volltextzugriff (PDF)

Vacuoles au sein des précurseurs myéloïdes médullaires dans le syndrome VEXAS : seuil et performances diagnostiques

La revue de medecine interne, 2022-12, Vol.43, p.A352-A353

2022

Volltextzugriff (PDF)

Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: LONG-TERM MUTATIONAL DYNAMICS IN DEL(5Q) MDS PATIENTS EARLY TREATED WTIH LENALIDOMIDE (SINTRAREV CLINICAL TRIAL). SAFE AND EFFECITIVE APPROACH REGARDING CLONAL EVOLUTION?

Leukemia research, 2023-05, Vol.128, p.107180, Article 107180

2023

Volltextzugriff (PDF)

The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation

Leukemia, 2010-11, Vol.24 (11), p.1852-1858

2010

Volltextzugriff (PDF)

Le risque d’ostéoporose ne diffère pas selon le pronostic hématologique des gammapathies monoclonales de signification indéterminée

Revue du rhumatisme (Ed. française : 1993), 2020-12, Vol.87, p.A73-A73

2020

Volltextzugriff (PDF)

Anémies hémolytiques auto-immunes à anticorps chauds associées aux syndromes myélodysplasiques et aux leucémies myélomonocytaires chroniques

La revue de medecine interne, 2024-06, Vol.45, p.A72-A72

2024

Volltextzugriff (PDF)

Suivi de l’utilisation de l’Eltrombopag en vie réelle en France à partir des données de l’Observatoire National de l’Insuffisance Médullaire (RIME) : étude REVEPI

La revue de medecine interne, 2021-12, Vol.42, p.A315-A315

2021

Volltextzugriff (PDF)

Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome

Oncogene, 2009-06, Vol.28 (22), p.2205-2218

2009

Volltextzugriff (PDF)

Sintra-Rev Clinical Trial: Preliminary Analysis of Efficacy and Safety at Week 12 of Treatment in MDS Del(5Q) and Transfusion Independence

Leukemia research, 2017-04, Vol.55, p.S52-S52

2017

Volltextzugriff (PDF)

Outcome of Lower-Risk Patients with Myelodysplastic Syndromes without 5Q Deletion after Failure of Erythropoiesis Stimulating Agents

Leukemia research, 2017-04, Vol.55, p.S33-S33

2017

Volltextzugriff (PDF)

P-284 Impact of cytogenetics and cytogeneticresponse on outcome in MDS treated with azacitidine (AZA)

Leukemia research, 2013-05, Vol.37, p.S150-S150

2013

Volltextzugriff (PDF)

O-017 A Phase I/II trial of erlotinib (ERLO) in higher-risk MDS after azacitidine (AZA) failure

Leukemia research, 2013-05, Vol.37, p.S16-S17

2013

Volltextzugriff (PDF)

Frontline azacitidine (AZA) or intensive chemotherapy (ICTx) in older AML patients

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.6530-6530

2010

Volltextzugriff (PDF)

1 – 25 von 588

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(502)
Mit Volltextzugriff
(530)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(475)
Französisch
(124)
Japanisch
(43)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

185 SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA AFTER CHRONIC MYELOMONOCYTIC LEUKEMIA: AN UNCOMMON CASE REPORT OF CLONAL EVOLUTION

Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia

205 A SINGLE CENTER REPORT OF THERAPEUTIC STRATEGIES IN PATIENTS WITH ATYPICAL CML (ACML) AND UNCLASSIFIED MDS/MPN (MDS/MPN-U)

P-283 Efficacy of salvage with decitabine (DAC) for high-risk (HR)-MDS and advanced CMML after azacitidine (AZA) treatment failure

Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine

Prévalence de l’ostéoporose chez les patients avec syndrome myélodysplasique

Les facteurs associés au risque d’ostéoporose au cours des syndromes myélodysplasiques

Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: MESENCHYMAL STROMAL CELLS OF THE BONE MARROW NICHE CONTRIBUTE TO THE PROINFLAMMATORY PHENOTYPE OF CMML MONOCYTES THROUGH IGFBP2

Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: CXCL8 SECRETED BY IMMATURE GRANULOCYTES INHIBITS WILD-TYPE STEM AND PROGENITOR CELL EXPANSION IN CHRONIC MYELOMONOCYTIC LEUKEMIA

Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: CMML PATIENTS WITH LOW EXPRESSION OF TP53 POINT TO AML TRANSFORMATION

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

Vacuoles au sein des précurseurs myéloïdes médullaires dans le syndrome VEXAS : seuil et performances diagnostiques

French consensus on myelodysplasic syndrome and chronic myelomonocytic leukemia: diagnostic, classification and treatment 2015 update by the Myelodysplasia French Group

Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: LONG-TERM MUTATIONAL DYNAMICS IN DEL(5Q) MDS PATIENTS EARLY TREATED WTIH LENALIDOMIDE (SINTRAREV CLINICAL TRIAL). SAFE AND EFFECITIVE APPROACH REGARDING CLONAL EVOLUTION?

The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation

Le risque d’ostéoporose ne diffère pas selon le pronostic hématologique des gammapathies monoclonales de signification indéterminée

Anémies hémolytiques auto-immunes à anticorps chauds associées aux syndromes myélodysplasiques et aux leucémies myélomonocytaires chroniques

Suivi de l’utilisation de l’Eltrombopag en vie réelle en France à partir des données de l’Observatoire National de l’Insuffisance Médullaire (RIME) : étude REVEPI

Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome

Sintra-Rev Clinical Trial: Preliminary Analysis of Efficacy and Safety at Week 12 of Treatment in MDS Del(5Q) and Transfusion Independence

Outcome of Lower-Risk Patients with Myelodysplastic Syndromes without 5Q Deletion after Failure of Erythropoiesis Stimulating Agents

P-284 Impact of cytogenetics and cytogeneticresponse on outcome in MDS treated with azacitidine (AZA)

Cytokine-like protein 1–induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML

O-017 A Phase I/II trial of erlotinib (ERLO) in higher-risk MDS after azacitidine (AZA) failure

Frontline azacitidine (AZA) or intensive chemotherapy (ICTx) in older AML patients

Suchergebnisse filtern